Partners at Ironbridge participated in the £1.3m capital raise. David Alexander has joined the Board as a non-executive director.

Censo Biotechnologies (www.censobio.com) enables the discovery and development of new targeted treatments for disease by using stem cell technology to predict how drugs will behave across a given population.